143 related articles for article (PubMed ID: 11748448)
1. Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas.
Puglisi F; Barbone F; Tell G; Aprile G; Pertoldi B; Raiti C; Kelley MR; Damante G; Sobrero A; Beltrami CA; Di Loreto C
Oncol Rep; 2002; 9(1):11-7. PubMed ID: 11748448
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas.
Puglisi F; Aprile G; Minisini AM; Barbone F; Cataldi P; Tell G; Kelley MR; Damante G; Beltrami CA; Di Loreto C
Anticancer Res; 2001; 21(6A):4041-9. PubMed ID: 11911289
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
4. Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers.
Moore DH; Michael H; Tritt R; Parsons SH; Kelley MR
Clin Cancer Res; 2000 Feb; 6(2):602-9. PubMed ID: 10690545
[TBL] [Abstract][Full Text] [Related]
5. Nuclear expression of apurinic/apyrimidinic endonuclease increases with progression of ovarian carcinomas.
Tanner B; Grimme S; Schiffer I; Heimerdinger C; Schmidt M; Dutkowski P; Neubert S; Oesch F; Franzen A; Kölbl H; Fritz G; Kaina B; Hengstler JG
Gynecol Oncol; 2004 Feb; 92(2):568-77. PubMed ID: 14766249
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of human apurinic/apyrimidinic endonuclease (APE/Ref-1) expression in rectal cancer treated with preoperative radiochemotherapy.
Kim JS; Kim JM; Liang ZL; Jang JY; Kim S; Huh GJ; Kim KH; Cho MJ
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):130-7. PubMed ID: 21075552
[TBL] [Abstract][Full Text] [Related]
7. Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC).
Kakolyris S; Giatromanolaki A; Koukourakis M; Kaklamanis L; Kanavaros P; Hickson ID; Barzilay G; Georgoulias V; Gatter KC; Harris AL
J Pathol; 1999 Nov; 189(3):351-7. PubMed ID: 10547596
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of Topoisomerase II in female breast cancer.
Koren R; Rath-Wolfson L; Ram E; Itzhac OB; Schachter B; Klein B; Gal R; Dreznik Z
Oncol Rep; 2004 Oct; 12(4):915-9. PubMed ID: 15375522
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
10. CD24 expression has a prognostic impact in breast carcinoma.
Athanassiadou P; Grapsa D; Gonidi M; Athanassiadou AM; Tsipis A; Patsouris E
Pathol Res Pract; 2009; 205(8):524-33. PubMed ID: 19243896
[TBL] [Abstract][Full Text] [Related]
11. Cysteine proteinase inhibitor cystatin A in breast cancer.
Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of p53 expression in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty KK
Anticancer Res; 1998; 18(1A):65-70. PubMed ID: 9568057
[TBL] [Abstract][Full Text] [Related]
13. Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance.
Freitas S; Moore DH; Michael H; Kelley MR
Clin Cancer Res; 2003 Oct; 9(13):4689-94. PubMed ID: 14581338
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
15. Differential cellular and subcellular expression of the human multifunctional apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme.
Duguid JR; Eble JN; Wilson TM; Kelley MR
Cancer Res; 1995 Dec; 55(24):6097-102. PubMed ID: 8521399
[TBL] [Abstract][Full Text] [Related]
16. Studies on p53 immunolocalisation in breast cancer and its prognostic significance.
Meenakshi A; Manoharan V
Hum Antibodies; 1999; 9(3):171-6. PubMed ID: 10690631
[TBL] [Abstract][Full Text] [Related]
17. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
Mylona EE; Alexandrou PT; Giannopoulou IA; Rafailidis PI; Markaki S; Keramopoulos A; Nakopoulou LL
Cancer Detect Prev; 2006; 30(2):111-7. PubMed ID: 16632244
[TBL] [Abstract][Full Text] [Related]
18. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
19. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.
Pellikainen J; Kataja V; Ropponen K; Kellokoski J; Pietiläinen T; Böhm J; Eskelinen M; Kosma VM
Clin Cancer Res; 2002 Nov; 8(11):3487-95. PubMed ID: 12429639
[TBL] [Abstract][Full Text] [Related]
20. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
